Gene signatures of drug resistance predict patient survival in colorectal cancer

Different combinations of 5-fluorouracil (5-FU), oxaliplatin, irinotecan and other newly developed agents have been used to treat colorectal cancer. Despite the advent of new treatment regimens, the 5-year survival rate for metastatic colorectal cancer remains low (~10%). Knowing the drug sensitivit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Y, Zhou, J, Tong, Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381104/
https://www.ncbi.nlm.nih.gov/pubmed/25179828
http://dx.doi.org/10.1038/tpj.2014.45

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381104/
https://www.ncbi.nlm.nih.gov/pubmed/25179828
http://dx.doi.org/10.1038/tpj.2014.45

Ejemplares similares